Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730841 | 0.85 | KMT2A (0.74) | KMT2ATSHRPOLBALDH1A1MEN1 | |
| SCHEMBL3503625 | 0.83 | TSHR (0.71) | KMT2ATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL10903940 | 0.82 | TSHR (0.68) | KMT2ATSHRPOLBALDH1A1LMNA | |
| SCHEMBL10904612 | 0.80 | TSHR (0.67) | KMT2ATSHRPOLBALDH1A1MAPK1 | |
| SCHEMBL10905952 | 0.80 | ALDH1A1 (0.72) | KMT2ATSHRPOLBALDH1A1LMNA | |
| SCHEMBL728908 | 0.79 | TSHR (0.65) | KMT2ATSHRPOLBALDH1A1LMNA | |
| SCHEMBL730827 | 0.79 | TSHR (0.65) | KMT2ATSHRPOLBALDH1A1LMNA | |
| SCHEMBL10904584 | 0.79 | ALDH1A1 (0.71) | KMT2ATSHRPOLBALDH1A1LMNA | |
| SCHEMBL3501643 | 0.78 | CYP2C19 (0.69) | KMT2ATSHRPOLBALDH1A1MEN1 | |
| SCHEMBL10904262 | 0.78 | KMT2A (0.64) | KMT2ATSHRPOLBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011163502-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR2, FPR3 | KMT2A 4493/4885TSHR 886/4885POLB 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.